We therefore propose that the co-expression of the SLC7A5/SLC3A2 complex could potentially be measured in ER+ breast cancer patients to identify those patients who will fail to benefit from endocrine therapy, potentially reducing the risk of relapse; its presence may also guide the clinician towards a rational choice of other alternative therapies for these patients. Here, SLC3A2 is linked to breast cancer.